Anne M Robinson Selected Research

Adalimumab (Humira)

1/2022	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
1/2022	Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
1/2020	Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
5/2019	Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
1/2019	The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
1/2019	Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
11/2018	Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.
7/2018	Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
7/2018	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
1/2018	Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne M Robinson Research Topics

Disease

27	Crohn Disease (Crohn's Disease) 01/2022 - 09/2009
5	Ulcerative Colitis 01/2022 - 02/2012
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019 - 11/2014
3	Inflammation (Inflammations) 01/2022 - 09/2011
3	Infections 01/2019 - 09/2011
2	Fistula 11/2018 - 07/2018
1	Hemorrhage 01/2019
1	Ileitis 10/2018
1	Arthralgia (Joint Pain) 01/2018
1	Lymphoma (Lymphomas) 01/2018
1	Arthritis (Polyarthritis) 01/2018
1	Ulcer 12/2017
1	Necrosis 12/2017
1	Opportunistic Infections (Opportunistic Infection) 12/2016
1	Herpes Zoster 12/2016
1	Body Weight (Weight, Body) 04/2015
1	Skin Neoplasms (Skin Cancer) 04/2014
1	Neoplasms (Cancer) 04/2014
1	Disease Progression 12/2013
1	Diarrhea 09/2011

Drug/Important Bio-Agent (IBA)

27	Adalimumab (Humira)FDA Link 01/2022 - 09/2009
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2016 - 09/2009
4	C-Reactive ProteinIBA 01/2022 - 05/2013
4	Immunologic Factors (Immunomodulators)IBA 01/2019 - 04/2014
3	Monoclonal AntibodiesIBA 04/2015 - 09/2009
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2016 - 09/2011
1	Prostaglandins AIBA 01/2019
1	risankizumabIBA 10/2018
1	Interleukin-23 (Interleukin 23)IBA 10/2018
1	SteroidsIBA 07/2018
1	Infliximab (Remicade)FDA Link 07/2018
1	2-mercaptopurineIBA 01/2018
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 12/2017
1	Prednisone (Sone)FDA LinkGeneric 12/2017
1	GelsIBA 10/2017
1	Immunosuppressive Agents (Immunosuppressants)IBA 12/2016
1	AlbuminsIBA 04/2015
1	Tumor Necrosis Factor InhibitorsIBA 02/2012
1	Bile Acids and Salts (Bile Acids)IBA 09/2011

Therapy/Procedure

11	Therapeutics 01/2022 - 01/2011
2	Biological Therapy 01/2022 - 11/2016